Bio-Techne and Regulus report ADPKD research progress



MINNEAPOLIS – Bio-Techne (NASDAQ:) Corporation (NASDAQ: TECH) and Regulus (NASDAQ:) Therapeutics Inc. announce continued technical and clinical collaboration following the company's announcement Positive topline results from a potential Phase 1b study for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This collaboration, which began in 2020, supports the development of ADPKD therapeutics targeting microRNA, specifically anti-miR-17.

Key clinical data for Regulus' investigational drug RGLS8429 were generated using Bio-Techne's Simple WesternTM platform and ExosomeDx CLIA laboratory services. These technologies automate the Western blot process and provide liquid biopsy-based diagnostics, respectively, thereby facilitating analysis of protein expression and identification of therapeutic proteins.

In this study, Regulus developed assays to measure polycystin 1 (PC1) and polycystin 2 (PC2) levels in urine samples. These biomarkers are important in ADPKD because affected patients often have lower levels of these proteins. These assays provide sensitive and quantitative readouts, which are critical for understanding the mechanism and pharmacodynamics of drugs.

Will Geist, President of Bio-Techne's Protein Sciences Division, expressed appreciation for the milestone achieved by the Regulus team and expressed enthusiasm for the continued collaboration. With a portfolio of thousands of products and fiscal 2023 net sales of more than $1.1 billion, Bio-Techne is designed to support the development of advanced therapies and improve healthcare worldwide.

Regulus Therapeutics, headquartered in San Diego, California, is dedicated to discovering and developing drugs targeting microRNA. The company's product pipeline is complemented by strong intellectual property rights in the microRNA space.

This announcement is based on a press release statement.

Investment Professional Insights

As Bio-Techne Corporation (NASDAQ: TECH ) continues to strengthen its partnership with Regulus Therapeutics, it's worth noting the company's financial metrics and market performance. Bio-Techne, known for its innovative platform in protein science, has a market capitalization of $13.03 billion, reflecting its important position in the biotechnology market. The company's price-to-earnings ratio is as high as 64.35, indicating that investors are willing to pay a premium for its earnings, perhaps due to the growth prospects and innovation advantages the company maintains in the industry.

InvestingPro data shows that as of the third quarter of 2024, Bio-Techne's revenue in the past 12 months was US$1.154 billion, with revenue growing 2.73%. This growth is modest but steady, which may reassure investors looking for steady progress in the biotech industry. In addition, the company's gross profit margin is as high as 67.01%, showing that the company can maintain profitability despite higher research and development costs.

From an investment perspective, Bio-Techne has been trading at a high price-to-book ratio of 6.47, indicating that the market is valuing it above its book value, likely due to the potential of its technology and its partnership with Regulus Therapeutics. One InvestingPro Tip to consider is that Bio-Techne's cash flow is sufficient to cover its interest payments, which is a positive sign of financial health, especially for a company in a capital-intensive industry. Additionally, the company has maintained its dividend for 17 consecutive years, which may be attractive to investors seeking income.

For investors looking for in-depth analysis and additional insights, Bio-Techne offers more InvestingPro Tips. These tips can provide further guidance on investment decisions, particularly in the dynamic biotechnology sector. Interested readers can explore these tips by visiting https://www.investing.com/pro/TECH and use the coupon code to take advantage of an additional 10% off annual or bi-annual Pro and Pro+ subscriptions PRONEWS24. Through this offer, investors have access to a wealth of information, including numerous additional tips listed on InvestingPro, to better understand the investment environment surrounding companies like Bio-Techne.

This article was generated with the support of artificial intelligence and reviewed by an editor. For more information, please see our terms and conditions.





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *